- Home
- FATE vs NMAI Comparison
FATE vs NMAI Comparison
Compare FATE & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- NMAI
- Stock Information
- Founded
- FATE 2007
- NMAI 2021
- Country
- FATE United States
- NMAI United States
- Employees
- FATE N/A
- NMAI N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- NMAI Investment Managers
- Sector
- FATE Health Care
- NMAI Finance
- Exchange
- FATE Nasdaq
- NMAI Nasdaq
- Market Cap
- FATE 406.5M
- NMAI 430.5M
- IPO Year
- FATE 2013
- NMAI N/A
- Fundamental
- Price
- FATE $2.02
- NMAI $12.37
- Analyst Decision
- FATE Buy
- NMAI
- Analyst Count
- FATE 11
- NMAI 0
- Target Price
- FATE $6.89
- NMAI N/A
- AVG Volume (30 Days)
- FATE 1.6M
- NMAI 74.8K
- Earning Date
- FATE 11-12-2024
- NMAI 01-01-0001
- Dividend Yield
- FATE N/A
- NMAI 13.14%
- EPS Growth
- FATE N/A
- NMAI N/A
- EPS
- FATE N/A
- NMAI 0.64
- Revenue
- FATE $13,447,000.00
- NMAI N/A
- Revenue This Year
- FATE N/A
- NMAI N/A
- Revenue Next Year
- FATE N/A
- NMAI N/A
- P/E Ratio
- FATE N/A
- NMAI $19.03
- Revenue Growth
- FATE N/A
- NMAI N/A
- 52 Week Low
- FATE $1.96
- NMAI $10.60
- 52 Week High
- FATE $8.83
- NMAI $12.55
- Technical
- Relative Strength Index (RSI)
- FATE 31.10
- NMAI 30.51
- Support Level
- FATE $2.33
- NMAI $12.42
- Resistance Level
- FATE $2.58
- NMAI $12.85
- Average True Range (ATR)
- FATE 0.25
- NMAI 0.15
- MACD
- FATE -0.04
- NMAI -0.01
- Stochastic Oscillator
- FATE 6.45
- NMAI 4.82
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.